# Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance

> **NCT02606266** · PHASE2,PHASE3 · TERMINATED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 1 (actual)

## Conditions studied

- Congenital Cytomegalovirus (CMV)

## Interventions

- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT02606266
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-11
- **Primary completion:** 2018-07-11
- **Final completion:** 2018-12-11
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** No eligibles patients
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02606266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02606266, "Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02606266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*